These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19938885)

  • 21. Fixed drug eruption and generalised erythema following etoricoxib.
    Augustine M; Sharma P; Stephen J; Jayaseelan E
    Indian J Dermatol Venereol Leprol; 2006; 72(4):307-9. PubMed ID: 16880582
    [No Abstract]   [Full Text] [Related]  

  • 22. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
    Lai KC; Lam SK; Chu KM; Wong BC; Hui WM; Hu WH; Lau GK; Wong WM; Yuen MF; Chan AO; Lai CL; Wong J
    N Engl J Med; 2002 Jun; 346(26):2033-8. PubMed ID: 12087138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etoricoxib: a French review of adverse effects.
    Prescrire Int; 2014 Feb; 23(146):45. PubMed ID: 24669387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
    Sung JJ; Lau JY; Ching JY; Wu JC; Lee YT; Chiu PW; Leung VK; Wong VW; Chan FK
    Ann Intern Med; 2010 Jan; 152(1):1-9. PubMed ID: 19949136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
    Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
    Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gastric protection and treatment with low-dose aspirin].
    Agustí-Escasany A; Vallano-Ferraz A
    Med Clin (Barc); 2006 Feb; 126(6):232-3. PubMed ID: 16510098
    [No Abstract]   [Full Text] [Related]  

  • 29. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
    Naesdal J; Wilson I
    Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.
    Lanas A; García-Rodríguez LA; Arroyo MT; Gomollón F; Feu F; González-Pérez A; Zapata E; Bástida G; Rodrigo L; Santolaria S; Güell M; de Argila CM; Quintero E; Borda F; Piqué JM;
    Gut; 2006 Dec; 55(12):1731-8. PubMed ID: 16687434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer.
    Luo JC; Huang KW; Leu HB; Chen LC; Hou MC; Li CP; Lu CL; Lin HC; Lee FY; Lee SD
    Aliment Pharmacol Ther; 2011 Sep; 34(5):519-25. PubMed ID: 21726257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review.
    Shiotani A; Manabe N; Kamada T; Fujimura Y; Sakakibara T; Haruma K
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():8-12. PubMed ID: 22486865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
    Lanza FL; Rack MF; Simon TJ; Quan H; Bolognese JA; Hoover ME; Wilson FR; Harper SE
    Aliment Pharmacol Ther; 1999 Jun; 13(6):761-7. PubMed ID: 10383505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
    Elnachef N; Scheiman JM; Fendrick AM; Howden CW; Chey WD
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1249-58. PubMed ID: 18729848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
    Curtis SP; Ko AT; Bolognese JA; Cavanaugh PF; Reicin AS
    Curr Med Res Opin; 2006 Dec; 22(12):2365-74. PubMed ID: 17265571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
    Scheiman JM; Yeomans ND; Talley NJ; Vakil N; Chan FK; Tulassay Z; Rainoldi JL; Szczepanski L; Ung KA; Kleczkowski D; Ahlbom H; Naesdal J; Hawkey C
    Am J Gastroenterol; 2006 Apr; 101(4):701-10. PubMed ID: 16494585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term tolerability of etoricoxib in patients with previous reactions to non-steroidal anti-inflammatory drugs.
    Di Leo E; Aloia AM; Nettis E; Cardinale F; Foti C; Distaso M; Ferrannini A; Vacca A
    Int J Immunopathol Pharmacol; 2009; 22(4):1131-4. PubMed ID: 20074479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.